Custom Recombinant Protein Production Services Market Report 2026

The custom recombinant protein production services market size has grown rapidly in recent years. It will grow from $5.79 billion in 2025 to $6.47 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to expansion of academic and clinical research activities, increased use of recombinant proteins in drug discovery, growth in biopharmaceutical R&D pipelines, availability of advanced expression technologies, rising demand for specialized research services.

The custom recombinant protein production services market size is expected to see rapid growth in the next few years. It will grow to $10.21 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing development of biologics and biosimilars, rising investments in precision medicine, expansion of contract research outsourcing, growing demand for scalable protein production, increasing adoption of advanced purification technologies. Major trends in the forecast period include increasing demand for custom protein expression services, rising use of mammalian expression systems, growing focus on high-purity protein production, expansion of rapid turnaround research services, enhanced emphasis on quality control and validation.

The increasing focus on targeted and personalized therapies is expected to fuel the growth of the custom recombinant protein production services market in the future. Targeted and personalized therapies are medical treatments designed to account for individual patient characteristics, such as genetic profile or specific disease markers, to improve treatment outcomes and minimize side effects. The rise in these therapies is supported by advances in precision medicine, which allow treatments to be tailored to individual patient biology, enhancing clinical results and therapeutic efficiency. Custom recombinant protein production services support targeted and personalized therapies by providing precisely engineered proteins necessary for patient-specific drug development, biomarker targeting, and advanced biologic treatments. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the growing focus on targeted and personalized therapies is driving the growth of the custom recombinant protein production services market.

Leading companies operating in the custom recombinant protein production services market are focusing on introducing innovative microbial expression platforms, such as the proprietary E. coli expression system, to boost protein production, improve scalability, and reduce costs, accelerating the delivery of next-generation biologics. A proprietary E. coli expression system is a specialized, engineered E. coli bacterial strain used to produce recombinant proteins and plasmid DNA with high yield, stability, and efficiency, often tailored for specific biotechnological or pharmaceutical applications. For example, in March 2025, WuXi Biologics (Cayman) Inc., a China-based contract research, development, and manufacturing organization (CRDMO), launched its new EffiX Microbial Expression Platform. The platform offers impressive titers of over 15 g/L for non-mAb recombinant proteins and more than 1 g/L for plasmid DNA. EffiX is positioned as a comprehensive solution for developing and manufacturing microbial-derived biologics, enhancing scalability, quality, and productivity across the biopharmaceutical industry.

In January 2025, NanoImaging Services Inc., a US-based structural biology and imaging company, acquired Proteos Inc. for an undisclosed amount. Through this acquisition, NanoImaging Services aims to integrate Proteos’ expertise in custom recombinant protein production with its advanced imaging and analytical capabilities, providing an end-to-end solution for structure-based drug discovery and protein research. Proteos Inc. is a US-based company specializing in custom recombinant protein production services for research and drug discovery applications.

Major companies operating in the custom recombinant protein production services market are Thermo Fisher Scientific Inc., Merck KGaA, Applied Biological Materials Inc., R&D Systems Inc., GenScript Biotech Corporation, Sino Biological Inc, Biointron Biological Inc., OriGene Technologies Inc., Crown Bioscience Inc., Premas Biotech, Eurofins Discovery, ATUM, BPS Bioscience Inc., Novoprotein Scientific Inc., Kempbio Inc., Proteos Inc., Trenzyme GmbH, LakePharma Inc., Icosagen AS, and ProteoGenix SAS.

Tariffs are impacting the custom recombinant protein production services market by increasing costs of imported reagents, laboratory instruments, chromatography systems, bioreactors, and consumables used in protein expression and purification workflows. Biotechnology and pharmaceutical companies in North America and Europe are most affected due to reliance on imported lab equipment, while Asia-Pacific faces higher costs for exporting specialized research services. These tariffs are increasing project costs and lengthening procurement timelines. However, they are also supporting local laboratory infrastructure development, regional supplier partnerships, and increased domestic production of critical research materials.

The custom recombinant protein production services market research report is one of a series of new reports that provides custom recombinant protein production services market statistics, including custom recombinant protein production services industry global market size, regional shares, competitors with a custom recombinant protein production services market share, detailed custom recombinant protein production services market segments, market trends and opportunities, and any further data you may need to thrive in the custom recombinant protein production services industry. This custom recombinant protein production services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Custom recombinant protein production services are specialized biotechnology offerings that focus on the design, expression, and purification of recombinant proteins tailored to specific customer needs. These services combine molecular cloning, expression platforms, purification methods, and quality assurance processes to deliver proteins for research, therapeutic, and industrial purposes. They support faster scientific advancement, facilitate biologic development, and address precise experimental or clinical requirements.

The primary product types of custom recombinant protein production services include antibodies, enzymes, cytokines, growth factors, and recombinant hormones. Antibodies are proteins produced to selectively bind specific target antigens for research, therapeutic, or diagnostic applications. These services rely on various expression systems, including mammalian, bacteria, insect, yeast, and other expression systems. They are applied across drug discovery, biopharmaceutical production, diagnostics development, academic research, and industrial enzymes, and are utilized by end users such as research institutes, biotechnology and pharmaceutical companies, contract research organizations, and other end-users.

The market value is defined as the revenues that enterprises gain from the sale of services and/or goods within the specified market and geography through contracts, service agreements, or grants in terms of the currency (in USD unless otherwise specified).

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.